Alpine Immune Sciences Announces Participation in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference
08/04/2022 - 04:05 PM
SEATTLE --(BUSINESS WIRE)--
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the company will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10th, 2022 , at 4:05 p.m. ET /1:05 p.m. PT .
A live webcast of the fireside chat will be available online in the investor relations section of the company’s website at https://ir.alpineimmunesciences.com/events . A replay of the presentation will be available on the company website for 90 days following the webcast.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com . Follow @AlpineImmuneSci on Twitter and LinkedIn .
View source version on businesswire.com : https://www.businesswire.com/news/home/20220804005858/en/
Investor Relations
Alex Sharif
Director, Investor Relations and Corporate Development
Alpine Immune Sciences, Inc.
206-788-4545
ir@alpineimmunesciences.com
Media Relations
Kelli Perkins
Red House
kelli@redhousecomms.com
Source: Alpine Immune Sciences, Inc.
Alpine Immune Sciences Inc
ALPN Rankings
#329 Ranked by Stock Gains
ALPN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Seattle
About ALPN
founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.